HuXBR1-402-G5-PNU synergizes with the BCL2 inhibitor venetoclax. (A) Loewe additivity synergy matrix with venetoclax and huXBR1-402-G5-PNU (left panel) or trastuzumab-G5-PNU (Tras-G5-PNU) (right panel) in the venetoclax-sensitive ROR1⁺ cell lines, 697 (top row) and Mino (bottom row). Synergy matrices display calculated Loewe additivity scores. Blue indicates doses in which synergy is found, and red indicates antagonism; green represents doses in which neither synergy nor antagonism is found. (B) BCL2 protein expression in ectopic BCL2 overexpressing (lane 1) and parental 697 (lane 2) (top) and corresponding actin protein expression on bottom. (C) Flow cytometry analysis of surface ROR1 expression comparison between parental (left) and BCL2 overexpression 697 cells (right). (D) Fifty percent effective concentration (EC50) of venetoclax treated parental (left) and BCL2-overexpressing (right). (E) Synergy matrix of combination venetoclax and huXBR1-402-G5-PNU in BCL2 overexpressing 697 cells. All experiments were completed in at least 3 independent experiments. Error bars indicate ± SE.